The short answer
STEP UP, registered as NCT05646706, was a completed phase 3b trial of once-weekly semaglutide 7.2 mg in 1,407 adults with obesity, three times the standard 2.4 mg weight-management dose. Wharton and colleagues published it in Lancet Diabetes and Endocrinology in November 2025.
Key facts
- Registration
- NCT05646706
- Acronym
- STEP UP
- Phase
- 3b
- Status
- Completed
- Enrolment
- 1,407
- Dose tested
- 7.2 mg once weekly
- Standard dose
- 2.4 mg for weight management
- Published
- Lancet Diabetes Endocrinol, Nov 2025
Why the question is not obvious
Receptor-mediated effects saturate. Once most receptors are occupied most of the time, adding more drug produces progressively less additional effect while adverse effects, which may follow different dose-response relationships, can continue rising. Whether a higher dose helps is therefore an empirical question about where the curve flattens, not an assumption.
What a phase 3b trial is
Phase 3b studies run after the pivotal trials and often after approval, addressing questions the registration programme did not: a new dose, a new population, a comparison the label does not cover. They are proper randomised trials, and they exist because approval settles fewer questions than it appears to.
Research material referenced
Retatrutide 10mg, third-party HPLC tested
Why the dose ceiling matters commercially
Semaglutide at 2.4 mg reported 13.7% in the SURMOUNT-5 head-to-head against tirzepatide's 20.2%. If a higher dose closes part of that gap, the competitive position changes without a new molecule. That is a considerably cheaper route to a better number than developing a new compound, which is why the trial was worth running.
The tolerability trade-off
Gastrointestinal adverse effects are the dose-limiting factor across this class, and they follow from GLP-1 receptor pharmacology itself rather than from any impurity or design flaw. Any dose increase has to be read alongside what happened to discontinuation, because a dose producing more weight reduction in those who tolerate it can produce less across everyone assigned to it.
Why this is the estimand question again
This is the situation the efficacy and treatment-policy estimands separate. The efficacy estimand answers what a higher dose does in people who stay on it; the treatment-policy estimand answers what it does across everyone randomised, including those who stopped. A higher dose can improve the first and worsen the second, and a single headline figure conceals which.
What this does not concern
Research material, and it is not dosing guidance for anything. Semaglutide is a licensed medicine and 7.2 mg is a dose arm in a registered trial conducted under clinical supervision. Nothing supplied here is semaglutide or an alternative to it.
Frequently asked questions
Is a higher dose automatically more effective?
No. Receptor-mediated effects saturate, so additional drug produces progressively less additional effect while adverse effects may keep rising.
Why does the estimand matter here?
A higher dose can improve results among those who stay on it while worsening them across everyone randomised, if discontinuation rises.
Continue researching
Related guides and reference material.
Primary sources & clinical trials
Published papers, trial registrations, regulator pages and company announcements. Links open the original.
- PubMedWharton S et al., Once-weekly semaglutide 7·2 mg in adults with obesity (STEP UP): a randomised, controlled, phase 3b trial. Lancet Diabetes Endocrinol 2025 (PMID 40961952)pubmed.ncbi.nlm.nih.gov
- TrialClinicalTrials.gov · STEP UP (NCT05646706)clinicaltrials.gov
- RefSURMOUNT-5: Tirzepatide as compared with semaglutide. NEJMnejm.org
Written and published by UK Peptides, the trading name of AURYXRESEARCH LTD (company 17388727, registered in England and Wales).
Questions or a correction? Email hello@ukpeptides.org or call +44 7426 987848.
More GLP-1 & Incretin Science articles
- How a Molecule Lasts a Month Instead of a WeekWeekly dosing comes from albumin binding. Monthly dosing needs something else - an antibody, and the recycling receptor that keeps it in circulation.
- Blocking and Activating the Same Receptor, in One ModelTirzepatide activates GIPR; MariTide blocks it. Both work. A February 2026 mouse study finally compared the two directions under matched conditions.
- Why Population-Specific Trials Are RunOASIS 2 studied oral semaglutide in an East Asian population. Why obesity thresholds and drug response differ, and what a dedicated trial establishes.
- The Question Underneath the Lean Mass DebateAll weight loss costs fat-free mass, including diet and surgery. The real questions are whether incretins cost more, and whether it has functional consequences.
- What Fat-Free Mass Actually ContainsBone, organs, water and blood-forming tissue all sit inside the fat-free compartment. Treating the number as a muscle measurement is a category error.